# Anuh Pharma share price today (Anuh Pharma Ltd, NSE: ANUHPHR)

> Anuh Pharma share price today: ₹81.15 at the NSE close on 3 November 2026, down 9.7% in a year. Anuh Pharma (NSE: ANUHPHR) is worth ₹813 crore, trades at a P/E of 17.0 and has closed between ₹70.21 and ₹94.62 over the past 52 weeks. > Anuh Pharma Ltd's results are improving, while its P/E is near the low end of its own history over 11 years, higher than only 27% of past readings. ANUHPHR · Pharma - API · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/anuh-pharma-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from the last 12 quarters
- Price: ₹81.15 (−9.7% in a year)
- P/E: 17.0× (lower than 73% of the last 11 years)
- Revenue (Sep 2026): ₹185 Cr (−0.5% on a year ago)
- Profit (Sep 2026): ₹11.0 Cr (+37.5% on a year ago)
- Operating margin: 9.0% (+3.0 points on a year ago)
- ROCE: 15%, FY26
- ROIC: 16.9%, against a 12.0% cost of capital: +4.9 points

The main question: profits are rising, but only 32% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Anuh Pharma share price today? Anuh Pharma Ltd's share price was ₹81.15 at the close on 3 November 2026. It has been rising for 7 weeks. That is 1.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹70 and ₹95, and at that close it sat 45% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 12 weeks in a row. Over the last 11 years the share price moved +70% while the NIFTY 500 moved +243%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Anuh Pharma this quarter? One change stood out: operating margin up 3 points on a year earlier. 1. Operating margin up 3 points on a year earlier 9% in the September 2026 quarter, from 6%. ## What are Anuh Pharma's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Anuh Pharma reported revenue of ₹185 crore, down 0.5% from ₹186 crore a year earlier, and a profit of ₹11.0 crore, up 37.5% from ₹8.00 crore. ### Anuh Pharma results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹185 crore | ₹186 crore | −0.5% |
| Profit | ₹11.0 crore | ₹8.00 crore | +37.5% |
| Earnings per share | ₹1.12 | ₹0.76 | +47.4% |
| Operating margin | 9.0% | 6.0% | +3.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Anuh Pharma share price history? Anuh Pharma closed at ₹81.15 on 3 November 2026, down 9.7% from ₹89.88 a year earlier (31 October 2025) and up 51.7% over five years. Its highest weekly close since April 2016 was ₹127.78 on 26 April 2024. ### Anuh Pharma share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹76.90 | +5.5% |
| 1 month ago · 1 Oct 2026 | ₹86.88 | −6.6% |
| 6 months ago · 30 Apr 2026 | ₹81.99 | −1.0% |
| 1 year ago · 31 Oct 2025 | ₹89.88 | −9.7% |
| 3 years ago · 3 Nov 2023 | ₹65.45 | +24.0% |
| 5 years ago · 4 Nov 2021 | ₹53.50 | +51.7% |
| 10 years ago · 4 Nov 2016 | ₹54.50 | +48.9% |
| Earliest weekly close in our records · 1 Apr 2016 | ₹47.70 | +70.1% |
| Highest weekly close since April 2016 · 26 Apr 2024 | ₹127.78 | −36.5% |
| Lowest weekly close since April 2016 · 2 Aug 2019 | ₹27.32 | +197.0% |
| 52-week high (weekly close) · 11 Sep 2026 | ₹94.62 | −14.2% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹70.21 | +15.6% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (560 weekly closes from 1 April 2016 to 3 November 2026.)

## What is the latest news on Anuh Pharma? 3 Nov 2026: Anuh Pharma closed at ₹81.15, up 5.5% on the week and down 6.6% on the month. Results for July to September 2026: Revenue down 0.5% and profit up 37.5% on a year earlier. ### Earlier

- 5 Aug 2026: ex-date for a dividend of ₹1.50 a share. - 15 Jul 2025: Bonus issue: 1 new share for every 1 held (ex-date). ## What dividend does Anuh Pharma pay? Anuh Pharma paid ₹1.50 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 1.85% at the ₹81.15 close on 3 November 2026. The last was a dividend of ₹1.50 a share, ex-date 5 August 2026. ### Anuh Pharma dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 5 Aug 2026 | ₹1.50 | Dividend | same day |
| 14 Aug 2025 | ₹1.50 | Dividend | 15 Aug 2025 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 1 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Anuh Pharma Ltd paid out 37% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Anuh Pharma on? Anuh Pharma is on 4 of our India lists: Momentum stocks, Dividend stocks, Penny stocks and Pharma stocks. - [Momentum stocks Market cap cr: 847.4401557668078](https://www.sectoralpha.in/momentum-stocks-india)
- [Dividend stocks Regular dividend yield (%): 1.77](https://www.sectoralpha.in/dividend-stocks-india)
- [Penny stocks Earnings growth, 12 months (%): 23.58](https://www.sectoralpha.in/penny-stocks-india)
- [Pharma stocks Market value (₹ crore): 847.4401557668078](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Anuh Pharma profitable? Anuh Pharma Ltd earned ₹11.0 Cr of net profit in the Sep 2026 quarter, +37.5% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹41.0 Cr. Over 10 years profit has grown 4.7% a year on average. That is 5.9% of the quarter's revenue. The same quarter a year earlier earned ₹8.0 Cr. For the full year, FY26 profit was ₹41.0 Cr (−12.8% on the year before). Why profit moved: revenue changed −0.5% on a year earlier and the margin moved +3.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +26.3% and revenue +7.2%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Anuh Pharma make, and is it growing? Anuh Pharma Ltd reported ₹185 Cr of revenue in the Sep 2026 quarter, −0.5% on the same quarter a year earlier. Over 10 years it has grown 9.0% a year on average. The last full year, FY26, came in at ₹772 Cr. The last four reported quarters add to ₹778 Cr. FY26 revenue was ₹772 Cr, +16.6% on the year before. Recent pace: the last four quarters grew +7.2% on average, against 9.0% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +6.6%, against +10.3% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +23.7%, against −10.7% a year (accelerating). ## How much of every ₹100 of sales does Anuh Pharma keep? Anuh Pharma Ltd's operating margin was 9.0% in the Sep 2026 quarter, 3.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 8.0% and 12.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +2.8 percentage points on the year while gross margin changed +3.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Anuh Pharma's profit turning into cash? Over the last 3 years, 32% of Anuh Pharma Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 its operations used ₹3.0 Cr of cash, against ₹41.0 Cr of profit. After ₹10.0 Cr of spending on assets, free cash was −₹13.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 32% of profit came in as cash: the cash cycle got 41 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 41 days longer. The next section looks at where the cash is stuck. ## Where does Anuh Pharma's cash go? Anuh Pharma Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 89 days in FY26, up from 48 days in FY21. It spent ₹33.0 Cr on assets over the last 3 years. Customers take 113 days to pay, and stock sits for 90 days on average. At FY26 sales of ₹772 Cr, each day of that cycle ties up about ₹2.1 Cr, so roughly ₹188 Cr is tied up in the business at any time. FY26: customers took 113 days to pay and stock sat for 90 days, about 3.0 months of sales sitting as stock, for a full cycle of 89 days, longer than FY21's 48. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 90 days. Customers pay about 113 days after that. Suppliers are paid at 114 days. Together that makes the 89-day cycle. Spending on assets: ₹33.0 Cr over the last 3 years, against ₹29.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Anuh Pharma's P/E ratio, and how does it compare with its own history? Anuh Pharma Ltd's P/E is 17.0×, near the low end of its own history: it has been lower only 27% of the time. Its usual P/E (the middle reading) is 19.7×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −13.3% while the price moved −9.7%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +8.7% a year; about +22.6% a year came from earnings growth and about −13.9 percentage points from the multiple (the market paying less); over 10 years the price moved +4.1% a year; about +9.6% a year came from earnings growth and about −5.5 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Anuh Pharma business getting better or worse? Anuh Pharma Ltd's business is turning around. Profit growth has swung from −22.4% at its low to +23.7%, improving for 4 quarters in a row, with ROCE steady at 17.9%. This is based on 12 quarters of 4 measures. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. ## How much does Anuh Pharma earn on its capital? Anuh Pharma Ltd earned a ROCE of 15% in FY26. That is up from a low of 10% in FY20. Its return on capital used (ROIC) is 4.9 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 5.3% net margin and 1.39× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 5.3% net margin × 1.39× asset turnover × 1.58× leverage (assets divided by equity) ≈ 11.6% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 16.9% − 12.0% = +4.9 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. The 16.9% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 15.2%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Anuh Pharma have too much debt? Anuh Pharma Ltd has total debt of ₹0.0 Cr against shareholder equity of ₹352 Cr as of Jun 2026, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.02 in FY22 to 0.00 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Anuh Pharma shareholding pattern? Promoters raised their stake in Anuh Pharma Ltd by 1.9 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 71.8% of the company. Foreign institutions moved +0.1 points over the same period, to 0.1%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: +1.9 points over 8 quarters, to 71.8%; Foreign institutions: +0.1 points over 8 quarters, to 0.1%; Domestic institutions: +0.0 points over 8 quarters, to 0.0%. Why the owners changed: promoters drove it (+1.9 points). They raised their stake step by step. ## How far is Anuh Pharma from balance-sheet trouble? For Anuh Pharma Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Anuh Pharma rank in its industry? 64.2 out of 100, rank 1 of 14 in Pharma - API, with 100% of the evidence available. Anuh Pharma Ltd scores 64.2 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 1. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 21.1 + 13.8 + 17.8 + 11.5 = 64.2. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Anuh Pharma compared with? Anuh Pharma ranks 1 of 14 Pharma - API companies on the 4-Factor Sector Score, with 64.2 out of 100. 1. Anuh Pharma Ltd this page ANUHPHR · breaking out · Evidence leans up · 100% evidence 64.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 6.6% · Profit 23.7% · Operating margin change 3 points · 100% evidence Capital efficiency 13.8/25 · ROCE 14.9% · Operating margin 9% · 100% evidence Valuation 17.8/20 · P/E 18.3× · PEG 0.31 · 100% evidence Relative strength 11.5/20 · Lead over its industry -7.9% · Lead over NIFTY 500 14.5% · 1 year -3.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21.1 + 13.8 + 17.8 + 11.5 = 64.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Senores Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/senores-pharmaceuticals-ltd) SENORES · quiet · Evidence leans up · 75% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.2/35 · Revenue 38.9% · Profit 62.4% · Operating margin change -1 points · 95% evidence Capital efficiency 16.4/25 · ROCE 15.1% · Operating margin 30% · 76% evidence Valuation 9.2/20 · P/E 39.1× · PEG n/a · 15% evidence Relative strength 7.4/20 · Lead over its industry -6.3% · Lead over NIFTY 500 12.6% · 1 year 47% · 100% evidence · 7 of 12 weeks ahead Exact sum: 28.2 + 16.4 + 9.2 + 7.4 = 61.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Innova Captab Ltd](https://www.sectoralpha.in/stocks/innova-captab-ltd) INNOVACAP · leader · Evidence leans up · 96% evidence 60.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 34.4% · Profit 18.5% · Operating margin change 1 points · 88% evidence Capital efficiency 13.0/25 · ROCE 15% · Operating margin 16% · 100% evidence Valuation 7.3/20 · P/E 38.1× · PEG 4.06 · 100% evidence Relative strength 15.8/20 · Lead over its industry 3.4% · Lead over NIFTY 500 25.3% · 1 year 23.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24 + 13 + 7.3 + 15.8 = 60.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Beta Drugs Ltd](https://www.sectoralpha.in/stocks/beta-drugs-ltd) BETA · losing its lead · Evidence leans up · 67% evidence 56.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/35 · Revenue 15.3% · Profit 26.2% · Operating margin change 1 points · 95% evidence Capital efficiency 18.4/25 · ROCE 19.2% · Operating margin 22% · 76% evidence Valuation 8.0/20 · P/E 38.5× · PEG n/a · 50% evidence Relative strength 10.5/20 · Lead over its industry n/a · Lead over NIFTY 500 11.2% · 1 year -3.1% · 25% evidence · 8 of 12 weeks ahead Exact sum: 19.8 + 18.4 + 8 + 10.5 = 56.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Ind-Swift Laboratories Ltd](https://www.sectoralpha.in/stocks/ind-swift-laboratories-ltd) INDSWFTLAB · leader · Evidence leans up · 82% evidence 56.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 29.9% · Profit -64.1% · Operating margin change 14.3 points · 95% evidence Capital efficiency 8.3/25 · ROCE 4.9% · Operating margin 19% · 76% evidence Valuation 7.1/20 · P/E 34.9× · PEG n/a · 50% evidence Relative strength 20.0/20 · Lead over its industry 71.6% · Lead over NIFTY 500 98.2% · 1 year 257.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21 + 8.3 + 7.1 + 20 = 56.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Wanbury Ltd](https://www.sectoralpha.in/stocks/wanbury-ltd) WANBURY · quiet · Evidence leans up · 81% evidence 55.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.0/35 · Revenue 3.6% · Profit 30% · Operating margin change -5.2 points · 88% evidence Capital efficiency 16.6/25 · ROCE 30.7% · Operating margin 9.8% · 100% evidence Valuation 19.2/20 · P/E 11.2× · PEG 0.34 · 100% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -19.7% · 1 year -27.9% · 25% evidence · 0 of 12 weeks ahead Exact sum: 12 + 16.6 + 19.2 + 7.5 = 55.3 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 7. [Gujarat Themis Biosyn Ltd](https://www.sectoralpha.in/stocks/gujarat-themis-biosyn-ltd) GUJTHEM · turning · Evidence leans up · 89% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.6/35 · Revenue 16.1% · Profit 6.7% · Operating margin change 9 points · 88% evidence Capital efficiency 18.1/25 · ROCE 18.1% · Operating margin 48% · 100% evidence Valuation 10.3/20 · P/E 97.1× · PEG 1.33 · 65% evidence Relative strength 7.2/20 · Lead over its industry -16.3% · Lead over NIFTY 500 3.7% · 1 year -21.7% · 100% evidence · 5 of 12 weeks ahead Exact sum: 19.6 + 18.1 + 10.3 + 7.2 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Aarti Drugs Ltd](https://www.sectoralpha.in/stocks/aarti-drugs-ltd) AARTIDRUGS · turning · Evidence leans up · 96% evidence 50.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.5/35 · Revenue 10.5% · Profit 1.1% · Operating margin change 1 points · 88% evidence Capital efficiency 13.4/25 · ROCE 12% · Operating margin 14% · 100% evidence Valuation 8.2/20 · P/E 20.6× · PEG 3.2 · 100% evidence Relative strength 12.0/20 · Lead over its industry -6.8% · Lead over NIFTY 500 15.8% · 1 year -11.3% · 100% evidence · 9 of 12 weeks ahead Exact sum: 16.5 + 13.4 + 8.2 + 12 = 50.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Jagsonpal Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jagsonpal-pharmaceuticals-ltd) JAGSNPHARM · breaking out · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue 6% · Profit -27% · Operating margin change -1 points · 100% evidence Capital efficiency 19.1/25 · ROCE 22.7% · Operating margin 21% · 100% evidence Valuation 6.4/20 · P/E 30.2× · PEG 3.39 · 100% evidence Relative strength 6.4/20 · Lead over its industry -10.7% · Lead over NIFTY 500 9.9% · 1 year -2.7% · 100% evidence · 7 of 12 weeks ahead Exact sum: 14.6 + 19.1 + 6.4 + 6.4 = 46.5 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 10. [Aarti Pharmalabs Ltd](https://www.sectoralpha.in/stocks/aarti-pharmalabs-ltd) AARTIPHARM · breaking out · Evidence leans down · 85% evidence 44.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 13.4% · Profit 6.7% · Operating margin change 4 points · 100% evidence Capital efficiency 12.4/25 · ROCE 10.7% · Operating margin 22% · 100% evidence Valuation 2.9/20 · P/E 30.4× · PEG 5.52 · 100% evidence Relative strength 11.8/20 · Lead over its industry n/a · Lead over NIFTY 500 22.9% · 1 year 2.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 17.8 + 12.4 + 2.9 + 11.8 = 44.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Fermenta Biotech Ltd](https://www.sectoralpha.in/stocks/fermenta-biotech-ltd) FERMENTA · losing its lead · Evidence leans down · 64% evidence 42.8 out of 100 Growth Capital Valuation Relative
12. [Kopran Ltd](https://www.sectoralpha.in/stocks/kopran-ltd) KOPRAN · breaking out · Evidence leans down · 81% evidence 41.5 out of 100 Growth Capital Valuation Relative
13. [Orchid Pharma Ltd](https://www.sectoralpha.in/stocks/orchid-pharma-ltd) ORCHPHARMA · losing its lead · Evidence leans down · 66% evidence 37.8 out of 100 Growth Capital Valuation Relative
14. [Themis Medicare Ltd](https://www.sectoralpha.in/stocks/themis-medicare-ltd) THEMISMED · quiet · Most evidence points down · 71% evidence 30.1 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API](https://www.sectoralpha.in/sectors/pharma-api), all 14 compared on one page. ## Which companies are close to Anuh Pharma in size? Anuh Pharma is the 12th largest of 14 Pharma - API companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Beta Drugs, Jagsonpal Pharmaceuticals, Fermenta Biotech and Kopran. Just below it: Themis Medicare and Wanbury. ### Pharma - API companies close in size

1. [Beta Drugs Ltd](https://www.sectoralpha.in/stocks/beta-drugs-ltd) ₹2,000 crore
2. [Jagsonpal Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jagsonpal-pharmaceuticals-ltd) ₹1,427 crore
3. [Fermenta Biotech Ltd](https://www.sectoralpha.in/stocks/fermenta-biotech-ltd) ₹1,229 crore
4. [Kopran Ltd](https://www.sectoralpha.in/stocks/kopran-ltd) ₹1,155 crore
5. Anuh Pharma Ltd ₹875 crore
6. [Themis Medicare Ltd](https://www.sectoralpha.in/stocks/themis-medicare-ltd) ₹873 crore
7. [Wanbury Ltd](https://www.sectoralpha.in/stocks/wanbury-ltd) ₹662 crore

[All 14 Pharma - API companies, largest first](https://www.sectoralpha.in/sectors/pharma-api#all-companies)

### Companies close in size in other industries

1. [Kalyani Cast-Tech Ltd](https://www.sectoralpha.in/stocks/kalyani-cast-tech-ltd) ₹878 crore · Castings - Steel/Alloy
2. [Finkurve Financial Services Ltd](https://www.sectoralpha.in/stocks/finkurve-financial-services-ltd) ₹876 crore · Finance & Investments - Others
3. Anuh Pharma Ltd ₹875 crore
4. [Bright Outdoor Media Ltd](https://www.sectoralpha.in/stocks/bright-outdoor-media-ltd) ₹875 crore · Entertainment & Media
5. [Unihealth Hospitals Ltd](https://www.sectoralpha.in/stocks/unihealth-hospitals-ltd) ₹875 crore · Hospitals/Medical Services

## What else do people ask about Anuh Pharma? ### What is Anuh Pharma's share price today? Anuh Pharma Ltd's share price is ₹81.15, −9.7% over the past year. The whole company is worth ₹813 Cr on the market. In the last 52 weeks it traded between ₹70 to ₹95; today it is 45% of the way up from the low, 1.3% below its 200-day average (as of 3 November 2026). ### What were Anuh Pharma's latest quarterly results? Anuh Pharma Ltd reported revenue of ₹185 Cr and net profit of ₹11.0 Cr for the Sep 2026 quarter. Revenue fell 0.5% and profit rose 37.5% compared with a year earlier. Earnings per share were ₹1.12. The operating margin was 9.0%, 3.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Anuh Pharma's market cap? Anuh Pharma Ltd's market capitalisation is ₹813 Cr at a share price of ₹81.15. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Anuh Pharma performing? Anuh Pharma Ltd's share price has been rising for 7 weeks. In its latest quarter, revenue fell 0.5% and profit rose 37.5% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 12 weeks running (as of 3 November 2026). ### Will Anuh Pharma's share price go up? This page does not forecast Anuh Pharma Ltd's share price. What it shows instead: the share price is ₹81.15, and it has been rising for 7 weeks. Its P/E of 17.0× is higher than 27% of its own last 11 years (as of 3 November 2026). ### Who owns Anuh Pharma? Promoters own 71.8% of Anuh Pharma Ltd, foreign institutions 0.1%, domestic institutions 0.0% and the public 28.1% (latest quarter). The biggest change over the last two years: Promoters raised their stake by 1.9 percentage points over 8 quarters (as of 3 November 2026). ### Does Anuh Pharma have too much debt? No, Anuh Pharma Ltd has little debt: its debt is 0.00× its equity, and its operating profit is 62 times its interest bill. FY26 borrowings were ₹0.0 Cr against equity of ₹352 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Anuh Pharma in its business cycle? Anuh Pharma Ltd's FY26 operating margin was 8.0%, against a 13-year range of 8.0% to 12.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 9.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Anuh Pharma story? The main question: profits are rising, but only 32% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Anuh Pharma a stock worth studying right now? What the numbers show: Anuh Pharma Ltd's results are improving, while its P/E is near the low end of its own history over 11 years, higher than only 27% of past readings. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Dividend stocks: https://www.sectoralpha.in/dividend-stocks-india
- Penny stocks: https://www.sectoralpha.in/penny-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.